23:59 , Aug 14, 2019 |  BC Extra  |  Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
21:23 , May 3, 2019 |  BioCentury  |  Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
19:41 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
18:16 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on an M1-mimicking synthetic peptide could help treat influenza. Screening of a combinatorial library of D-peptides against CD8 + T cell clones specific for the immunodominant...
13:03 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

EC approves Diurnal's Alkindi

Diurnal Group plc (LSE:DNL) said the European Commission approved Alkindi (Infacort) as a replacement therapy to treat adrenal insufficiency in individuals less than 18 years old. Diurnal plans to launch Alkindi in 2Q18, but told...
15:04 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends Diurnal's Alkindi for pediatric adrenal insufficiency

EMA's CHMP recommended approval of Alkindi (Infacort) from Diurnal Ltd. (Cardiff, U.K.) as replacement therapy for pediatric adrenal insufficiency. The company expects a final decision in February and anticipates a launch in 2Q18. The product...
21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...
20:06 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

RV521: Ph I data

Top-line data from a Phase I trial in 48 healthy volunteers showed that single and multiple ascending doses of oral RV521 were well tolerated with no significant treatment-related adverse events reported. A separate blinded, placebo-controlled,...
21:50 , Apr 20, 2017 |  BC Week In Review  |  Company News

Diurnal, Clinigen sales and marketing update

Clinigen launched a patient access program in Europe to provide Diurnal’s cortisol deficiency candidates Infacort and Chronocort on a named-patient basis to patients who have no other treatment options. Infacort is under EMA review to...